Navigation Links
Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Date:1/6/2009

SEATTLE, Jan. 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has received notification that the NASDAQ Listing Qualifications Panel has granted CTI's request to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Market, which will be effective with the open of trading on Thursday, January 8, 2009. CTI's shares will continue to trade under the ticker symbol CTIC.

CTI's continued listing on The NASDAQ Capital Market is subject to CTI evidencing compliance with all applicable requirements for continued listing on The NASDAQ Capital Market, including the $35 million market value of listed securities requirement or its alternatives, as set forth in NASDAQ Marketplace Rule 4310(c)(3), by February 12, 2009. The Company expects to comply with all applicable requirements for continued listing on The NASDAQ Capital Market by February 12, 2009; however, there can be no assurance that it will be able to do so.

As disclosed on September 6 and October 10, 2008, CTI was previously notified by NASDAQ regarding its non-compliance with the $50 million market value of listed securities requirement for continued listing on The NASDAQ Global Market. In response, CTI appeared before the NASDAQ Listing Qualifications Panel at a hearing at which it requested the transfer of its listing to The NASDAQ Capital Market pursuant to its plan to evidence compliance with the $35 million market value of listed securities requirement for continued listing on that market.

The NASDAQ Capital Market is one of the three market tier designations for NASDAQ-listed stocks and operates in substantially the same manner as The NASDAQ Global Market. Securities listed on The NASDAQ Capital Market must satisfy all applicable qualification requirements for NASDAQ securities, and companies listed on The NASDAQ Capital Market must meet certain financial requirements and adhere to NASDAQ's corporate governance standards.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These risks and uncertainties include, without limitation, the Company's ability to achieve compliance with the NASDAQ Capital Market's continued listing requirements by February 12, including the market value of listed securities requirement, as well as other risks and uncertainties that could affect the Company's business operations and the development of the Company's products including the Company's need to raise additional capital, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation, the potential failure of a product to prove safe and effective for treatment of a specific condition, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling the product(s). You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

     Media Contact:
     Dan Eramian
     T: 206.272.4343
     C: 206.854.1200
     E: media@ctiseattle.com
    http://www.CellTherapeutics.com/press_room

     Investors Contact:
     Ed Bell
     T: 206.272.4345
     Lindsey Jesch Logan
     T : 206.272.4347
     F : 206.272.4434
     E: invest@ctiseattle.com
    http://www.CellTherapeutics.com/investors

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Horizon Therapeutics Announces Senior Management Appointments
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
3. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
4. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
5. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
6. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
7. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
8. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
9. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
10. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... the results of its 2016 Annual General Meeting, which was ... China . At the Annual ... of KPMG Huazhen LLP as the independent auditors of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building ... team building events, new program offerings and company expansion. , This is ... to include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 ... Company, has expanded its customisable SureSeq™ NGS panel range with ... - allowing fast and cost-effective study of variants in familial ... copy number variation (CNV) detection on a single small panel ... and hotspot content. This includes all exons for LDLR ...
Breaking Biology Technology:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):